A5103282839- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- COVID-19 Clinical Research Studies
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- Polyomavirus and related diseases
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Complement system in diseases
- Protein Degradation and Inhibitors
- Cytomegalovirus and herpesvirus research
- Renal Transplantation Outcomes and Treatments
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Immune Cell Function and Interaction
- T-cell and Retrovirus Studies
- Immunotherapy and Immune Responses
- Prenatal Screening and Diagnostics
- Immunodeficiency and Autoimmune Disorders
- Cancer Treatment and Pharmacology
- Lymphoma Diagnosis and Treatment
Jahn Ferenc Dél-Pesti Kórház és Rendelőintézet
2020-2025
Országos Reumatológiai és Fizioterápiás Intézet
2020-2025
Unified Szent István and Szent László Hospital
2017-2024
Erasmus MC Cancer Institute
2023
Hungarian National Blood Transfusion Service
2023
Országos Idegsebészeti Tudományos Intézet
2022
University of Münster
2022
KU Leuven
2022
National Center for Epidemiology
2021
Semmelweis University
2018
Objectives Uncontrolled thromboinflammation plays an important role in the pathogenesis of coronavirus disease (COVID-19) caused by SARS-CoV-2 virus. Complement was implicated as key contributor to this process, therefore we hypothesized that markers complement profile, indicative for activation state system, may be related severity and mortality COVID-19. Methods In prospective cohort study samples 102 hospitalized 26 outpatients with PCR-confirmed COVID-19 were analyzed. Primary outcome...
Abstract Background Assessment of measurable residual disease (MRD) is rapidly transforming the therapeutic and prognostic landscape a wide range hematological malignancies. Its value in acute lymphoblastic leukemia (ALL) has been established MRD measured at end induction increasingly used to guide further therapy. Although detectable immediately before allogeneic hematopoietic cell transplantation (HCT) known be associated with poor outcomes, it unclear if or what extent this differs...
Introduction While complement is a contributor to disease severity in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, all three pathways might be activated by the virus. Lectin pathway activation occurs through different pattern recognition molecules, including mannan binding lectin (MBL), protein shown interact with SARS-CoV-2 proteins. However, exact role of and its key molecule MBL COVID-19 still not fully understood. Methods We therefore investigated two...
Endothelial and complement activation were both associated with immunothrombosis, a key determinant of COVID-19 severity, but their interrelation has not yet been investigated. We aimed to determine von Willebrand factor (VWF) antigen (VWF:Ag) concentration, VWF collagen binding activity (VWF:CBA), disintegrin metalloproteinase thrombospondin type 1 motif, member 13 (ADAMTS13) (ADAMTS13:Ac), ratios in hospitalized patients, investigate how these parameters constellation relate disease...
Allogeneic hematopoietic cell transplantation (alloHCT) with myeloablative conditioning based on total body irradiation (TBI) is widely used for the treatment of adults acute lymphoblastic leukemia (ALL). TBI most frequently administered in combination either cyclophosphamide (Cy/TBI) or etoposide (Vp/TBI). The goal this study was to retrospectively compare these two regimens. Adult patients Ph-negative ALL treated alloHCT first second complete remission who received Cy/TBI (n = 1346) Vp/TBI...
Multiple myeloma (MM) accounts for 10% of haematological malignancies. Overall survival (OS) has improved in recent years due to increased use autologous stem cell transplantation (ASCT) the treatment newly diagnosed MM and advent novel agents, including proteasome inhibitors, immunomodulatory drugs monoclonal antibodies. To assess trends ASCT patient selection, choice induction regimen, depth response survival, we performed a retrospective analysis all patients undergoing first European...
A randomized study (acronym: MC-FludT.14/L Trial II) demonstrated that fludarabine plus treosulfan (30 g/m²) was an effective and well tolerated conditioning regimen for allogeneic hematopoietic cell transplantation (allo-HCT) in older patients with acute myeloid leukemia (AML) myelodysplastic syndrome (MDS). To further evaluate this regimen, all 252 aged 50 to 70 years were compared similar patients, who underwent allo-HCT after fludarabine/melphalan (140 mg/m²) (FluMel) or busulfan (12.8...
At present, neither specific curative treatment nor vaccines for novel coronavirus 2019 (COVID-19) are available. There is an urgent need to look alternative strategies COVID-19 especially in the case of severe and/or critically ill patients with cytokine release syndrome (CRS).Convalescent plasma proved increase survival rates other viral infections. Therefore, convalescent could be a promising option patients.In our article, we present first two Hungarian infection treated fresh frozen...
We compared outcomes of adult patients with secondary acute myeloid leukemia (sAML) versus de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) post-transplant cyclophosphamide (PTCy). Seventeen hundred and eleven (sAML-231, novo-1480) in first complete remission transplanted from 2010 to 2021, were included. Patients younger, median age 55.8 60.8 years, p < 0.0001, had better transplantation comorbidity index (HCT-CI) ≥ 3 21.3% 40.8%, 0.0001 Karnofsky performance...
Large randomized clinical trials in severe Coronavirus Disease 2019 (COVID-19) patients have proven efficacy of intravenous tocilizumab. Our aim was to describe the laboratory parameters predicting in-hospital mortality with tocilizumab administration COVID-19 associated cytokine release syndrome (CRS).We evaluated high-dose (8 mg/kg) and critically ill adult fulfilling predefined strict CRS criteria. A single-centre, prospective, observational cohort study carried out among consecutive (≥18...
The advent of novel agents for multiple myeloma (MM) is cause a re-examination the incidence second primary malignancies (SPMs). We examined SPM rate in MM patients who were enrolled prospective observational CALM (Collaboration to Collect Autologous Transplant outcome Lymphoma and Myeloma) study. Between 2008 2012, 3204 with underwent first autologous hematopoietic stem cell transplantation. Plerixafor was used as mobilizing agent poor (or potentially poor) mobilization defined by...
Graft versus host disease (GVHD) prophylaxis with posttransplantation cyclophosphamide (PTCY) has been established to reduce severe GVHD, and thereby potentially reducing nonrelapse mortality (NRM) after allogeneic stem cell transplantation (alloSCT). We evaluated the predictive capacity of NRM-risk scores in patients receiving PTCY-based GVHD prophylaxis, subsequently developed validated a novel PTCY-specific model. Adult (n = 1861) AML or ALL first complete remission who received alloSCT...
Abstract Purpose: Allogeneic hematopoietic cell transplantation (allo-HCT) is recommended in first complete remission (CR1) patients with acute myeloid leukemia (AML) harboring FMS-like tyrosine kinase 3–internal tandem duplication (FLT3-ITD). We assessed changes over time transplant characteristics and outcomes AML age 60 years younger a FLT3-ITD. Experimental Design: identified 1,827 adult (median 49 years, range 18–60) FLT3-ITD intermediate karyotype, allografted between 2012 2021 CR1....